EIB supports antimicrobial resistance research

The rise of drug-resistant infections and superbugs, which could kill 10 million people a year by 2050 (more than cancer kills today), is becoming a major threat. Antimicrobial drugs are becoming less effective and the world is not developing enough new solutions to keep up. If we don’t take action now, the global costs of facing this challenge in later stages could amount to around USD 100 trillion. The European Commission, the European Investment Bank and the European Federation of Pharmace...
Shares